Lead-212 PSV359 Therapy for Patients With Solid Tumors
← catalyst calendarNCT06710756 · readout in 530 d
Sponsored by Perspective Therapeutics (industry) · CATX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
112estimated
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-28 | actual | When the study began enrolling |
| Primary completion | 2028-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-05-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Ductal Adenocarcinoma
- Gastric Cancer
- Esophageal Cancer
- Colorectal Cancer
- Ovarian Cancer
- Head and Neck Cancer
- Sarcoma
- Mesothelioma
Interventions
- Drug: [203Pb]Pb-PSV359
- Drug: [212Pb]Pb-PSV359
Primary outcomes
what the primary-completion date above is the date OFDetermination of safety and tolerability of [203Pb]Pb-PSV359
measured 30 days (±1day) post dose
Determination of safety and tolerability of [212Pb]Pb-PSV359
measured Up to 3 years
To determine the recommended phase 2 dose of [212Pb]Pb-PSV359
measured Up to approximately 6 months
Publications
- PMID 42306799 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CATX's whole pipeline · Catalyst calendar · Every registered study · What changed